Share The miniature implantable telescope (IMT) was approved by the FDA one year ago. Since then, researchers have continued to track the use of the device.  After two years of study, they have concluded that in appropriate patients, it improves vision, improves quality of life and, though expensive, appears to be worth the investment.

The IMT is used for patients with end-stage wet macular degeneration. They are legally blind and there is no other treatment currently available to them. Recipients must be willing to undergo not only the surgery but also extensive vision training afterwards.  The training is essential for the success of the implant, as the brain needs to learn a different way to see.

A cataract extraction is first performed and then the IMT is placed in the eye where a normal intraocular lens would usually go after cataract surgery.  A person who has already had a cataract removed would not be eligible for the IMT in that eye.  The device magnifies images, which is another reason that vision training is required.

The study was published in Ophthalmology, the journal of the American Academy of Ophthalmology.  According to the article, "By the end of the two-year study, vision improved from 20/326 to 20/141 in 76 patients who received the 3X model IMT.  Most patients could once again see people's faces rather then just blurring outlines, and could get around the market or their backyard on their own."

The FDA will continue to monitor the IMT for 5 years to review safety and effectiveness. The cost of the device and procedure, with related costs is about $18,500.

August 2011